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Abstract
We studied the a-oxidation of phytanic acid in human fibroblasts of controls and patients affected with classical Refsum
disease, rhizomelic chondrodysplasia punctata, generalized peroxisomal disorders and peroxisomal bifunctional protein
deficiency. Cultured fibroblasts were incubated with phytanic acid, after which medium and cells were collected separately.
2-Hydroxyphytanic acid and pristanic acid were measured in the medium and cells by stable isotope dilution gas
chromatography mass spectrometry. In controls, 2-hydroxyphytanic acid and pristanic acid could be detected in the medium
after incubation with phytanic acid, proving that a-oxidation of phytanic acid via 2-hydroxyphytanoyl-CoA to pristanic acid
was active and intermediates were excreted into the medium.
In cells from patients with a defective a-oxidation Refsum disease, rhizomelic chondrodysplasia punctata and
.generalized peroxisomal disorders 2-hydroxyphytanic acid and pristanic acid were low or not detectable, showing that in
these disorders the hydroxylation of phytanoyl-CoA to 2-hydroxyphytanoyl-CoA is deficient.
In cells with a peroxisomal b-oxidation defect, 2-hydroxyphytanic acid and pristanic acid were formed in amounts
comparable to those in the controls. q 1997 Elsevier Science B.V.
Keywords: Phytanic acid; Pristanic acid; Zellweger syndrome; Refsum disease; Rhizomelic chondrodysplasia punctata
1. Introduction
Phytanic acid 3,7,11,15-tetramethylhexadecanoic
.acid undergoes a-oxidation to pristanic acid
 .2,6,10,14-tetramethylpentadecanoic acid . The
Abbreviations: DHAPAT, dihydroxyacetonephospate acyl-
transferase; alkyl-DHAP-synthase, alkyldihydroxyacetonephos-
phate synthase
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mechanism of the a-oxidation process is still incom-
pletely understood, although part of the pathway has
been elucidated recently. It is now clear, from the
w x w xwork of Pahan 1,2 and Watkins 3,4 that phytanic
acid is activated to its coenzyme A ester prior to
oxidation. Hereafter, a hydroxyl group is introduced
in the a-position, yielding 2-hydroxyphytanoyl-CoA.
The enzyme catalysing this reaction is a dioxygenase,
 2q.with iron Fe , 2-ketoglutarate and ascorbate as
w x  .cofactors 5–7 . The next step s , decarboxylation of
2-hydroxyphytanoyl-CoA, yields pristanic acid or
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pristanoyl-CoA and a one carbon compound. It was
long thought that this one carbon moiety was CO ,2
but it is now clear that formate is the primary reac-
w xtion product 7,8 . The formate is partially excreted in
urine and partially converted into CO , as was shown2
w x  .in vivo 9 Fig. 1 .
The a-oxidation of phytanic acid most probably
takes place in peroxisomes, at least partly. After
w xconflicting reports, in which mitochondria 10 , per-
w x w xoxisomes 11,12 and endoplasmic reticulum 13 were
all mentioned to be sites of a-oxidation, it was
recently found that the first step, hydroxylation, is
w xperoxisomal 5–7 . The earlier finding of accumula-
tion of phytanic acid in several peroxisomal disorders
already pointed to the peroxisome as the organelle in
which a-oxidation takes place.
In classical Refsum disease, deficiency of the
dioxygenase catalysing the conversion of phytanoyl-
CoA into 2-hydroxyphytanoyl-CoA was found to be
w xthe sole biochemical abnormality 6 . The biochemi-
cal basis of rhizomelic chondrodysplasia punctata
 .RCDP , another disorder in which phytanic acid
accumulates in plasma, is a defect in the import of
w xproteins with a PTS2 sequence into peroxisomes 14 .
This results in the occurrence of several biochemical
abnormalities in RCDP patients, including deficient
plasmalogen biosynthesis, an unprocessed but active
peroxisomal 3-ketoacyl-CoA thiolase and a defi-
ciency of phytanoyl-CoA hydroxylase which is the
basis for the phytanic acid accumulation. In general-
ized peroxisomal disorders, in which no functionally
active peroxisomes are present in liver and other
organs, both phytanic acid and pristanic acid accumu-
late. In addition to those disorders in which a-oxida-
tion is deficient, phytanic acid also accumulates in
peroxisomal b-oxidation defects. This is believed to
be due to inhibition of the a-oxidation pathway by
accumulating pristanic acid. This hypothesis is sup-
ported by the highly elevated ratio of pristanic acidr
w xphytanic acid in plasma of these patients 15 .
Recent experiments from our group demonstrated
that not only in Refsum disease, but also in RCDP
and generalized peroxisomal disorders the accumula-
tion of phytanic acid is caused by a deficiency of the
Fig. 1. Phytanic acid a-oxidation. Phytanic acid is first activated to its coenzyme A thioester, after which it is converted into
2-hydroxyphytanoyl-CoA. After decarboxylation by yet unknown enzymes, formate and pristanic acid or pristanoyl-CoA are formed.
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w xfirst enzyme in phytanic acid a-oxidation 6,16–18 .
This was concluded from experiments using liver
biopsies from patients. So far, no such studies have
been performed in human skin fibroblasts. This is an
essential step, since liver biopsy specimens are avail-
able from few patients only. The results obtained are
described below.
2. Materials and methods
2.1. Materials
L-Carnitine and defatted bovine serum albumin
 .BSA were purchased from Sigma, St. Louis, MO;
the cell culture media, antibiotics and fetal calf serum
 .FCS were obtained from Gibco BRL, Grand Island,
NY. Phytanic acid, pristanic acid, 2-hydroxyphytanic
w 2 x wacid, 3-methyl- H 2-hydroxyphytanic acid and 2-32 xmethyl- H pristanic acid were synthesized as de-3
w xscribed previously 15,19 .
2.2. Cell culture and preparations
Fibroblasts were cultured in Eagle’s minimal es-
sential medium containing non-essential amino acids
 .MEM , 10% FCS and antibiotics. Studies were con-
ducted using human skin fibroblasts from the 6th to
20th passages. Protein concentrations were deter-
w xmined by the method of Bradford 20 with BSA as
standard.
2.3. Fibroblast incubations
Aliquots from stock solutions of phytanic acid in
ethanol were prepared by completely evaporating the
ethanol under a stream of nitrogen. The residues were
dissolved in a solution of defatted BSA in medium.
The molar ratio of fatty acid to BSA was 4:1.
All incubations were performed in triplicate. Skin
 .fibroblasts 0.2–0.6 mg protein were subcultured in
25 cm2 flasks and left to grow for 24 h, after which
the medium was replaced with 3.5 ml of freshly
prepared bicarbonate-buffered MEM medium con-
taining 10% FCS, antibiotics, 0.4 mM L-carnitine and
0.2 mM phytanic acid bound to BSA. Cells were
incubated for a period of 96 h at 378C in humidified
5% CO r95% air. After the incubation period, the2
reaction medium was collected. The cells were har-
vested by trypsinization, washed twice in MEM
medium and resuspended in 300 ml water.
2.4. Cell lines
One control cell line was obtained from the Ameri-
 .can Cell Culture Repository GM 0833A . The other
4 control cell lines were from patients not affected
with a peroxisomal or mitochondrial disorder.
The fibroblast cell lines from patients affected with
Refsum disease were from patients described previ-
w xously 21,22 . Phytanoyl-CoA hydroxylase in a fresh
liver biopsy of one of these showed an activity of
w x-2% of control values 6 .
Table 1
Levels of 2-hydroxyphytanic acid and pristanic acid in medium of human fibroblasts after 96 h of incubation with phytanic acid. Each cell
line was incubated in triplicate. Values represent mean"S.D.
Cell line analyzed 2-hydroxyphytanic acid Pristanic acid Ratio 2-OH-phytanicr
 .  . pristanic acidnmolrmg protein nmolrmg protein
 .Controls ns5 2.1"1.3 10.6"4.0 0.2"0.1
a .Refsum disease ns2 n.d. n.d. —
 .RCDP ns2 n.d. n.d. —
b  .GPD 1 ZS n.d. n.d. —
 .GPD 2 N—ALD 0.4"0.0 n.d. —
 .GPD 3 IRD 0.2"0.0 0.1"0.0 1.7"0.1
 .GPD 4 IRD 0.8"0.1 0.3"0.1 2.7"0.2
 .GPD 5 IRD 0.5"0.1 0.9"0.2 0.6"0.1
 .Bifunctional protein def. ns5 3.1"1.3 13.4"5.1 0.2"0.0
a
n.d.: not detectable.
b Generalized peroxisomal disorder.
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The RCDP patients whose fibroblasts were used
showed all clinical and biochemical hallmarks of the
disease. In all cases extensive studies were performed
in fibroblasts de novo plasmalogen biosynthesis,
C26:0 oxidation, phytanic acid and pristanic acid
oxidation, DHAPAT activity, alkyl-DHAP-synthase
activity, immunoblot analysis of acyl-CoA oxidase
.and thiolase, catalase immunofluorescence and
plasma concentrations of phytanic acid, pristanic
. w xacid and very long chain fatty acids 23 .
The patients affected with generalized peroxisomal
disorders from whom we obtained cell lines showed
the typical biochemical abnormalities as described in
these disorders. In all cases extensive studies were
done in cultured fibroblasts and only those cell lines
were selected which displayed a generalized loss of
peroxisomal functions due to the absence of peroxi-
somes, as shown by immunofluorescence studies.
 .Patient 2 GPD 2 in Table 1 was found to belong to
w xcomplementation group 1 24 . No information about
complementation analysis of the other patients af-
fected with a generalized peroxisomal disorder was
available.
The bifunctional protein deficient cell lines were
w xfrom patients previously described 25 .
2.5. Measurement of 2-hydroxyphytanic acid and
pristanic acid
Aliquots of 200 ml of the incubation medium and
75 ml of the cell suspension were prepared for analy-
sis of 2-hydroxyphytanic acid and pristanic acid. For
wanalysis of pristanic acid, 0.05 nmol 2-methyl-
2 xH pristanic acid was added to the medium or the3
cell aliquots as internal standard. For analysis of
w 2 x2-hydroxyphytanic acid, 0.1 nmol 3-methyl- H 2-3
hydroxyphytanic acid was added as internal standard.
The sample preparation procedures and gas chro-
matography mass spectrometry measurements were
w xsimilar to those described before 15,26 .
3. Results
3.1. Phytanic acid metabolism in control fibroblasts
After incubating control human fibroblasts with
phytanic acid, both 2-hydroxyphytanic acid and pris-
tanic acid were formed. The amounts of intermediates
formed after 96 h of incubation are depicted in Table
1. Measurement of the intermediates in the cells and
 .the medium revealed that virtually all )95% of the
intermediates were found only in the medium.
3.2. Phytanic acid metabolism in a-oxidation defi-
cient cells
In classical Refsum disease, neither 2-hydroxy-
phytanic acid nor pristanic acid could be detected
after incubation with phytanic acid, neither in the
medium nor in the cells. In medium and cells from
RCDP patients, no 2-hydroxyphytanic acid or pris-
tanic acid were found either.
Five cell lines from patients affected with a gener-
alized peroxisomal disorder were investigated. One
 .cell line patient 1 in Table 1 was obtained from a
patient affected with Zellweger syndrome. In this
case, no formation of 2-hydroxyphytanic could be
observed, proving that the hydroxylation step was
 .deficient. The second cell line patient 2 in Table 1
was from a patient affected with neonatal adrenoleu-
codystrophy. In this case, a small amount of 2-hy-
droxyphytanic acid was found in the medium, whereas
no pristanic acid was detectable. The third, fourth and
 .the fifth cell lines patient 3, 4 and 5 in Table 1 were
from patients affected with infantile Refsum disease.
The amount of 2-hydroxyphytanic acid found was
low or comparable to the amount in controls, the
amount of pristanic acid 3–12% of controls.
3.3. Phytanic acid metabolism in b-oxidation defi-
cient cells
In medium and cells deficient in peroxisomal bi-
functional protein, 2-hydroxyphytanic acid and pris-
tanic acid were formed. The concentrations of both
these intermediates were comparable to those in the
controls.
4. Discussion
As the physiology of phytanic acid a-oxidation
has remained a puzzle through the years, it is still not
 .known which step s of this process are deficient in
the various disorders in which phytanic acid accumu-
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lates. However, the first step, hydroxylation of phy-
tanoyl-CoA yielding 2-hydroxyphytanoyl-CoA, was
w x w xrecently elucidated in rat 5,7 and human 6 and its
deficiency in liver from patients suffering from clas-
sical Refsum disease, RCDP and generalized peroxi-
w xsomal disorders was reported 6,16,17 . In Refsum
disease, this deficiency is probably due to mutations
in the gene coding for phytanoyl-CoA hydroxylase.
In RCDP, the biochemical defect is a disturbance in
the peroxisomal import of proteins containing the
w xperoxisomal targetting signal PTS2 14 . It can thus
be hypothesized that phytanoyl-CoA hydroxylase
contains a PTS2 targetting signal, resulting in a defi-
cient import into peroxisomes and reduced activity of
the enzyme in case of RCDP. In generalized peroxi-
somal disorders, deficiency of phytanoyl-CoA hy-
droxylase, which is localized in peroxisomes, can be
ascribed to the absence of functional peroxisomes.
Substantiation of these hypotheses awaits the identifi-
cation of phytanoyl-CoA hydroxylase protein and
gene.
In this paper, we investigated the a-oxidation of
phytanic acid in cultured human fibroblasts. The
measurement of 2-hydroxyphytanic acid and pristanic
acid in the medium enabled us to study the hydroxyl-
ation and decarboxylation steps of phytanic acid a-
oxidation separately. The absence of 2-hydroxy-
phytanic acid and pristanic acid in the medium from
cells from patients affected with Refsum disease or
RCDP, in contrast with the higher, clearly detectable
amounts in controls, show the deficient conversion of
phytanoyl-CoA into 2-hydroxyphytanoyl-CoA in
these disorders, which is in line with the results of
w xJansen et al. in human liver specimens 6,16 .
In cells from patients with a generalized peroxiso-
mal disorder, the residual activity we sometimes find
seems to correlate with the milder clinical presenta-
tion of these patients. The most severe form of this
type of disorder, Zellweger syndrome, did not show
residual activity of phytanic acid a-oxidation in fi-
broblasts, whereas in the mildest form, infantile Ref-
sum disease, significant residual activity was found.
The observation that the 2-hydroxyphytanic acidr
pristanic acid ratio in these patients is elevated as
compared to controls, suggests that the hydroxylation
step in these disorders has a higher residual activity
than the second step, the decarboxylation.
The absence of residual activity in RCDP, in con-
trast with the residual activity in generalized peroxi-
somal disorders, provides an explanation for the dif-
ference in phytanic acid plasma concentrations in
these disorders. The highest phytanic acid accumula-
tions in plasma are found in Refsum disease and
RCDP. In generalized peroxisomal disorders, the
w xplasma concentrations are usually lower 27 , which
can now be explained on the basis of the higher
residual activity of a-oxidation.
The finding of deficiencies of phytanoyl-CoA hy-
droxylase in RCDP and generalized peroxisomal dis-
orders raises the question why elevated levels of
2-hydroxyphytanic acid are found in plasma from
patients affected with these disorders, as reported by
w xten Brink et al. 15 . When comparing the 2-hydroxy-
phytanic acid levels with the phytanic acid levels it is
clear that the amount of 2-hydroxyphytanic acid in
these patients is relatively low. This may point to a
deficient but not completely absent activity of phy-
tanoyl-CoA hydroxylase. However, 2-hydroxy-
phytanic acid may also originate from the diet. A
deficiency in the breakdown of this compound, as
may be the case in generalized peroxisomal disorders
and RCDP, can result in levels which are higher than
in controls. A deficiency of not only the first but also
 .the other step s of phytanic acid a-oxidation may
also be the explanation for the results of an in vivo
w xstudy performed by ten Brink et al. 22 .
Under the experimental conditions used in this
study, we do not find an indication for a reduced
phytanic acid a-oxidation in bifunctional protein de-
ficient cell lines. This is in contrast with the findings
w xof McGuinness 25 but in agreement with Wanders
w x23 .
The studies described in this paper were performed
in intact human cells in culture. This is different from
most other studies concerning the individual steps of
a-oxidation, which are performed in isolated or-
w xganelles or in permeabilized whole cells 18,7 . Not
only are our experimental conditions more physio-
logical, they also enable us to study cell lines ob-
tained from different patients and to perform each
experiment several-fold. Furthermore, the analytical
methods used in this study enabled us to demonstrate
formation of 2-hydroxyphytanic acid and pristanic
acid from phytanic acid in cultured fibroblasts, which
w xwas found before by Tsai et al. 28 , but could not be
w xconfirmed by others 29 . In addition, our quantitative
( )N.M. Verhoe˝en et al.rBiochimica et Biophysica Acta 1361 1997 281–286286
measurements revealed the presence of residual activ-
ity of both steps of a-oxidation in some cell lines
with a generalized peroxisomal disorder.
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